Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes.

Trial Profile

Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2014

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Glucose metabolism disorders; Hypertension
  • Focus Pharmacodynamics
  • Acronyms AMARYLIS
  • Most Recent Events

    • 29 Mar 2014 Trial status changed to completed as reported by European Clinical Trials Database.
    • 26 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top